XBIO
NASDAQ
$2.81
Xenetic Biosciences Inc (XBIO)
Xenetic Biosciences, Inc., a biopharmaceutical company, is focused on advancing XCART, a customized chimeric antigen receptor T (CAR T) platform technology designed to target patient-specific tumor neoantigens. The company is headquartered in Framingham, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Target: $40 (+1323.49%)
Market Cap
$6.65M
P/B Ratio
0.94
Revenue 5Y CAGR
+41.05%
Free Cash Flow Yield
-27.38%
Price Chart
Valuation
Market Cap$6.65M
P/S2.15
P/B0.94
Profitability
Total Revenue (TTM)$3.19M
Gross Profit (TTM)$3.19M
EBITDA-$2.23M
Profit Margin-56.6%
Operating Margin-62.2%
EPS-$1.23
Financial Health
Free Cash Flow Yield-27.38%
Growth & Risk
EPS 5Y CAGR-40.47%
Revenue 5Y CAGR+41.05%
FCF 5Y CAGR-17.57%
Beta (5Y)0.77
Sharpe Ratio0.36